Aminazin - instructions, indications, composition, method of administration. Aminazin: instructions for use Intramuscular and intravenous administration

Compound

Contains active substance chlorpromazine hydrochloride .

The dragee contains 50 or 100 mg of this substance. Auxiliary elements: sunflower oil, talc, gelatin, sucrose, wax, starch syrup, titanium dioxide, iron oxide.

The solution contains 25 mg of chlorpromazine per ml.

Release form

Dragee, solution for intravenous and intramuscular administration, tablets

pharmachologic effect

Aminazin is antipsychotic drug, neuroleptic by pharmacological group.

It has antiemetic, antihistamine and hypotensive effects.

Pharmacodynamics and pharmacokinetics

The active ingredient is a phenothiazine derivative. The drug has antiemetic, sedative, antipsychotic, mild hypothermic, vasodilating, local irritating, moderate m-anticholinergic effects.

The antipsychotic effect is achieved by blocking the dopamine D2 receptors of the mesocortical and mesolimbic systems. The antipsychotic effect is manifested in the elimination of delirium, hallucinations and other productive symptoms of psychosis.

Aminazine helps to stop various types of psychomotor agitation, reduces the severity of psychotic fear, aggressiveness. Sedation is achieved by blockade of reticular pharmacy adrenergic receptors located in the brain stem.

The drug inhibits conditioned reflex activity (especially motor-defensive receptors), reduces the spontaneity of motor activity, reduces sensitivity to exogenous and endogenous stimuli with preserved consciousness, relaxes skeletal muscles. Prescribing large dosages causes drowsiness.

Blockade of dopamine receptors D2 receptors in the vomiting center in trigger zone , as well as blockade of the vagus nerve in the gastrointestinal tract, provide an antiemetic effect. Aminazine has a weak effect on m-cholinergic receptors, a pronounced effect is observed in relation to alpha-adrenergic receptors.

The medication is able to completely eliminate the effects caused by ... The hypothermic effect is provided by the blockade of dopamine receptors located in the hypothalamus. The medication increases heart rate, lowers blood pressure, has a pronounced cataleptogenic effect , weak antihistamine effect, reduces the permeability of the capillary walls. With blockade of dopamine receptors, the production of prolactin by the pituitary gland increases. With intramuscular administration, sedation develops after 15 minutes, with oral administration - after 2 hours. Tolerance to antihypertensive and sedative effects develops after 1 week.

When taken orally, the antipsychotic effect is observed on days 4-7. The most pronounced therapeutic effect lasts from 6 weeks to six months.

Indications for the use of Aminazin

In psychiatric practice, the drug is used to treat psychomotor agitation in patients with. The drug is prescribed for chronic psychosis, with hypomanic agitation, acute delusional states, psychopathy, insomnia, anxiety, mental illness, accompanied by agitation, anxiety, fear, from which pills are often used.

Also indications for the use of Aminazin are: alcoholic psychosis , stubborn, " indomitable"Vomiting, nausea. With persistent pain, the drug enhances the effect of analgesic medications.

The medicine is prescribed for diseases accompanied by increased muscle tone: tetanus (combination therapy with barbiturates), after suffering cerebrovascular accidents.

Previously, Aminazin was used as part of "lytic" mixtures (for artificial).

In anesthesiology, a medication is prescribed to potentiate general anesthesia, for premedication .

In dermatological practice, the drug is used for itchy dermatoses ... The drug is prescribed for treatment acute intermittent porphyria .

Contraindications

Aminazine is not used in coma of any etiology, with pronounced suppression of the functions of the nervous system, with severe pathology of the cardiovascular system, with intolerance to the active substance, with progressive diseases of the spinal cord and brain of a systemic nature, with, with ulcerative lesions of the digestive tract .

Due to the risk of developing hepatotoxic reactions, Aminazin is prescribed with caution. With breast cancer, with pathological changes in the blood, with hyperplasia of the prostate , with closed-angle glaucoma, with Parkinson's disease, myxedema, epilepsy, vomiting, cachexia, Reye's syndrome, the drug is prescribed with caution to elderly patients.

Side effects of Aminazin

Consider what side effects of Aminazin are. At the first stages of therapy, dry mouth is noted, increased sleepiness , paresis of accommodation, constipation, dizziness, appetite disorders, tachycardia, severe orthostatic hypotension, decreased potency, urinary retention, sleep disorders, frigidity, drop in blood pressure.

Long-term therapy with chlorpromazine causes neuroleptic depression , cramps of the tongue, muscles of the neck, floor of the mouth, extrapyramidal disorders , akathisia, akineto-rigid phenomena, delayed reaction to stimuli, mental changes, hypercoagulation, inhibition of bone marrow hematopoiesis, cardiac arrhythmias, cholestatic jaundice, gynecomastia, hyperplolactinemia , galactorrhea, skin pigmentation, oliguria, diarrhea, vomiting, neuroleptic malignant syndrome. With intramuscular injection, infiltrates may form; with intravenous infusion - phlebitis .

Instructions for the use of Aminazin (Way and dosage)

The drug is taken orally, injected intramuscularly, intravenously.

Aminazin tablets, instructions for use

The initial daily dosage in psychiatric practice is 25-100 mg (for 1-4 doses). Gradually, the amount of the drug is increased every 3-4 days by 25-50 mg until the desired effect is achieved. In case of anxiety before surgery, the medication is prescribed 2-3 hours before the surgery. The maximum one-time consumption is 300 mg, per day - 1.5 g.

Solution

A 2.5% solution is injected intravenously and intramuscularly.

The initial dose is 25-50 mg. Before intramuscular administration, the drug solution is diluted in 2-5 ml of solution (0.25-0.5%), or in a solution of sodium chloride 0.9%. Aminazine is administered deeply intramuscularly. Before surgical interventions in case of anxiety, patients are injected intramuscularly with the drug at the rate of 0.55 mg per 1 kg of weight 2 hours before the proposed surgical treatment. With tetanus, 0.55 mg / kg is injected intramuscularly every 8 hours, the infusion rate is 1 mg / 2 minutes.

Maximum one-time intramuscular injection of 150 mg, per day - 1 g.

Maximum one-time intravenous injection - 100 mg, per day - 250 mg.

In pediatric practice, only special, children's forms of the drug are used.

Overdose

Overdose is manifested by blurred visual perception, hyperreflexia or areflexia ... It is also noted cardiotoxic effect in the form of shock, drop in blood pressure, development heart failure , cardiac arrest, changes in the QRS complex on the electrocardiogram.

The neurotoxic effect is manifested by coma, stupor, drowsiness, seizures, confusion, agitation, respiratory depression, pulmonary edema, vomiting, muscle stiffness, hypothermia, or hyperpyrexia .

Requires the appointment of enterosorbents, gastric lavage. With the development of arrhythmia, phenytoin is injected intravenously, with the formation of heart failure, an appointment is recommended cardiac glycosides ... When blood pressure drops, vasopressors ( , norepinephrine). indicated for the development of seizures. At effective , diphenyltropine. Within five days, control over the work of the cardiovascular system, the respiratory system is required, consultation of a psychotherapist is required. Dialysis has not been proven to be effective.

Interaction

Aminazine can weaken the vasoconstrictor effect of the drug. Some manifestations ototoxicity (severe dizziness, tinnitus) while taking ototoxic medications can be masked during treatment with chlorpromazine.

The drug reduces the severity of the antiparkinsonian effect levodopa (as a result of blockade of dopamine receptors). A similar effect is observed when taking , amphetamine, guanethidine.

The drug enhances the anticholinergic effect of other drugs, but at the same time there is a decrease in its own antipsychotic effect. The medication is compatible with antidepressants , antipsychotics, anxiolytics. Long-term use of antipyretics, analgesics is not recommended due to the risk hyperthermia .

Development risk neuroleptic malignant syndrome increases significantly with joint therapy with tricyclic antidepressants, MAO inhibitors, manprotiline.

Lithium preparations, antiparkinsonian drugs, antacid medicines interfere with the absorption of chlorpromazine.

Terms of sale

We need a recipe.

Storage conditions

In a dark place protected from children at a temperature of 15-25 degrees Celsius.

Best before date

No more than 2 years.

special instructions

Therapy with the drug requires control over the pulse, the work of the hepatic, renal systems. To prevent a sharp drop in blood pressure after intravenous and intramuscular injections, the patient is placed on a couch for 1.5-2 hours.

Due to the fact that the drug can cause photosensitivity , it is recommended to avoid ultraviolet rays, radiation. It is not allowed to take ethanol during the therapy period. It is required to completely eliminate the likelihood of getting chlorpromazine on the mucous membranes, skin.

The medicinal product affects driving.

It is described on Wikipedia as Chlorpromazine.

INN: Chlorpromazine.

Recipe in Latin:

Rp .: Sol. Aminazini 2.5% 1.0
D. t. d. No. 10 in amp.
S.

Aminazine and alcohol

Aminazin's analogs

Matching ATX level 4 code:

An analogue is the drug Chlorpromazine Hydrochloride.

Recipe for Chlorpromazine in Latin:

Example how to do it right write a prescription for chlorpromazine (chlorpromazine) in Latin in tablets, dragees and ampoules. Aminazine is used to treat mental illness accompanied by psychomotor agitation, fear, insomnia; Meniere's disease, for the correction of alcoholic psychoses, as well as for stopping vomiting in pregnant women and patients with itchy dermatitis.

Recipe for chlorpromazine in ampoules in Latin:

Rp .: Sol. Chlorpromazini 2.5% - 5.0 D.t.d.N 6 in amp. S. i / m 2 times a day

In acute psychosis, chlorpromazine is prescribed intravenously in a stream:

Rp .: Sol. Chlorpromazini 2.5% - 2.0 D.t.d. No. 1 in amp. S. Intravenous bolus, diluting the drug in 20 ml of 40% glucose solution

Prescription for chlorpromazine (chlorpromazine) in dragee in Latin

Rp. Dragee Chlorpromazini 0.1 D.t.d.N 10 S. 1 tab. * 2 times a day

Prescription in Latin for chlorpromazine tablets

Rp. Tab. Chlorpromazini 0.05 D.t.d.N 20 S. 1 tab. * 3 times a day

The information is intended for specialists and students of medical universities. Do not self-medicate, consult a doctor for qualified help.

General information:

Active substance: Chlorpromazine (INN)
Pharmacological group: Antipsychotics
Prescription form: N 148-1 / y-88
Trade names:

• chlorpromazine
• chlorpromazine

Important!

Aminazine is contraindicated in decompensation of cardiovascular pathology, incl. hypotension, severe kidney and liver diseases, gastric ulcer and duodenal ulcer, during lactation.

Content

The medicine belongs to the pharmacological group of neuroleptics. It is known to be an effective remedy for neutralizing mental disorders. The use of the drug requires careful adherence to the rules specified in the instructions and taking into account possible negative reactions.

Composition of the preparation

Aminazine comes in two forms:

1. Solution for parenteral administration (clear yellow-green liquid) contains 25 mg of chlorpromazine hydrochloride per 1 ml, packed in ampoules of 2 ml, 10 pcs. in a pack. Auxiliary components: anhydrous sodium sulfite, ascorbic acid, sodium metabisulfite, water, sodium chloride.
2. Dragee (covered with a yellow-orange film) contains 25, 50 or 100 mg of chlorpromazine hydrochloride per 1 pc., Packed in 10 pcs. in a pack. Auxiliary components: sunset yellow dye, calcium hydrogen phosphate, titanium dioxide, microcrystalline cellulose, hypromellose, potato starch, talc, colloidal silicon dioxide, polyethylene glycol, stearic acid, calcium stearate.

Indications for taking the drug Aminazin

The drug belongs to antipsychotics from phenothiazine derivatives. It has antipsychotic, sedative effects, weakens or completely eliminates delusions, hallucinations, and relieves psychomotor agitation.

The remedy reduces the severity of affective reactions, anxiety, has antiemetic activity.

Taking high doses can cause hypnotic effects.

Indications for the use of Aminazin:

• mental illness against the background of psychomotor agitation, fear, insomnia;
• acute alcoholic psychosis;
• vomiting of pregnant women;
• itchy dermatitis;
• Meniere's disease;
• chronic paranoid or hallucinatory-paranoid state;
• agitation in manic-depressive psychosis;
• psychomotor agitation in schizophrenia (catatonic, hebephrenic, hallucinatory-delusional syndromes);
• mental disorder with epilepsy;
• agitated depression in presenile psychosis;
• neurotic diseases against the background of increased muscle tone;
• persistent sleep disturbances;
• causalgia, other pain;
• treatment or prevention of vomiting during radiation therapy, taking antineoplastic agents.

Who is the drug contraindicated for?

The remedy is prescribed with caution for urolithiasis, cholelithiasis, rheumatic heart disease, acute pyelitis, rheumatism. Contraindications to its use:

• stomach ulcer, duodenal ulcer;
• severe hypotension;
• diseases of the liver, kidneys, stomach, hematopoiesis;
• decompensated heart failure;
• intolerance to the components of the composition;
• progressive diseases of the brain, spinal cord;
• late stage of bronchiectasis;
• brain injury;
• myxedema;
• coma;
• thromboembolism;
• heart defects in the stage of decompensation.

Method of using Aminazin

Aminazin tablets are taken orally, the solution is administered intravenously or intramuscularly. The method of treatment and the choice of the form of the drug depends on the age, characteristics of the patient, and the type of disease. Each type has its own instructions for use.

Tablets

The instruction indicates that Aminazin tablets are taken after meals. The course of treatment lasts from 3 weeks to 4 months. Adults are supposed to take 25-75 mg per day in 2-3 doses, then increase the dose to 75-100 mg in 3-4 doses. Sometimes it is permissible to prescribe 1 g per day.

With diseases of the liver, heart and blood vessels, in old age, the dose is reduced by 2-3 times. With prolonged hiccups, take 25-50 mg 3-4 times a day. For children over 5 years old, the drug is prescribed for the treatment of autism and schizophrenia, the dose is half to three times less than an adult, the maximum daily dosage will be 75 mg in several doses.

Intramuscular and intravenous administration

Aminazine in ampoules is administered intramuscularly or intravenously. A single dose of 150 mg is used intramuscularly, 600 mg daily. Intramuscularly, 1.5 ml of a 2.5% solution is injected up to 3 times a day. In case of acute mental agitation, 2-3 ml of a 2.5% solution in 20 ml of a 40% glucose solution is injected intravenously. A single dose will be 100 mg, a daily dose - 250 mg.

Children over one year old are prescribed a dosage of 250-500 mcg per 1 kg of body weight, over 5 years old with a body weight of up to 23 kg - 40 mg per day, 5-12 years old with a body weight over 23 kg - 75 mg daily. Weakened patients are administered 300 mg intramuscularly or 150 mg intravenously per day.

Possible negative reactions

• nausea, vomiting, dyspepsia, cholestatic jaundice;
• arterial hypotension, collapse, tachycardia;
• parkinsonism;
• photosensitivity;
• dizziness;
• disorientation;
• allergic reactions, skin rash, erythema, dermatitis, skin pigmentation;
• akathisia, blurred vision, visual disturbances;
• dystonic extrapyramidal reactions, tardive dyskinesia;
• violation of thermoregulation;
• psychotropic convulsions;
• tetanus;
• slowing down the heart rate;
• increased sensitivity to ultraviolet light;
• leukopenia, agranulocytosis;
• difficulty urinating;
• violation of the menstrual cycle, impotence, gynecomastia;
• increase in body weight;
• deposition of chlorpromazine in the cornea and lens, this side effect leads to an acceleration of the aging process of the lens.

Overdose

In case of an overdose, vague speech, a wobbly gait, bradycardia, difficulty breathing, weakness, and confusion are observed. The patient suffers from weakened reflexes, drowsiness, seizures, hypotension, depression. Exceeding the dose of Aminazine can cause neuroleptic syndrome, persistent hypotension, coma, hypothermia, toxic hepatitis.

Symptomatic therapy is prescribed. There is no specific antidote, hemodialysis is ineffective. In case of collapse, caffeine, cordiamine, mezaton are injected, antihistamines are prescribed for dermatitis, and Cyclodol is prescribed for neurological disorders.

special instructions

1. Phenothiazines are prescribed with caution in case of pathological changes in the blood picture, impaired liver function, alcohol intoxication, Reye's syndrome, breast cancer, predisposition to glaucoma, Parkinson's disease. Care should be taken in cardiovascular diseases, gastric and duodenal ulcers, urinary retention, epileptic seizures, chronic respiratory diseases, especially in children.
2. With long-term administration of Aminazine, it is recommended to control the picture of peripheral blood, prothrombin index, liver and kidney functions, to undergo examinations with an ophthalmologist and a neurologist.
3. When hyperthermia appears, the appointment is canceled.
4. During treatment, alcohol intake is unacceptable, this enhances the depressing effect on the central nervous system, respiration.
5. During therapy, you should carefully drive a car and operate machinery.
6. The combination of Aminazine with tricyclic antidepressants, monoamine oxidase inhibitors, Maprotiline is capable of increasing the risk of developing neuroleptic malignant syndrome.
7. Simultaneous administration of the drug with anticonvulsants leads to a decrease in the threshold of convulsive readiness, with drugs for the treatment of hyperthyroidism - to the development of agranulocytosis, with hypotonic drugs - to hypotension.
8. Amphetamines are antagonists of Aminazine, antacids based on magnesium or aluminum hydroxide slow down its absorption in the stomach, hormonal contraceptives - enhance. Cimetidine - reduces concentration.
9. The remedy enhances the anticholinergic effect of the drugs of the same name, the sedative effect of Zolpidem, Zopiclone, when combined with anticholinesterase drugs, leads to muscle weakness, myasthenia gravis, with Amitriptyline - to tardive dyskinesia, paralytic ileus.
10. Chlorpromazine inhibits the action of Guanethidine, leads to hyperglycemia when combined with Diazoxide, hyperpyrexia - with Doxpein, myoclonus - with Morphine, increases the concentration of Imipramine, Propranolol, Phenytoin in the blood, suppresses the effect of Levodopa and Ephedrine.
11. The embryotoxic effect of the agent has been experimentally established.
12. The drug is stored at 15-25 degrees for 2 years, out of the reach of children.

Aminazin's analogs

Drugs with the same or a different composition with a similar effect can replace the agent. These include.

International non-proprietary name

Synonyms

Chlorpromazine

Pharmacotherapeutic group

Neuroleptic

Compound

1 tablet contains 50 mg of chlorpromazine hydrochloride
1 tablet contains 100 mg of chlorpromazine hydrochloride

pharmachologic effect

A neuroleptic from the group of phenothiazine derivatives. It has antipsychotic and sedative effects. Weakens or completely eliminates delusions and hallucinations, relieves psychomotor agitation, reduces affective reactions, anxiety, anxiety, and lowers motor activity. Has antiemetic effect. May cause hypnotic effects when used in high doses. Causes extrapyramidal disorders, increases the release of prolactin. Has alpha-adrenergic blocking, antihistamine and weak m-anticholinergic activity, lowers blood pressure. The mechanism of action of the drug is not fully understood. It is believed that many of the central effects are due to blockade of dopamine receptors in various parts of the brain. The sedative effect, apparently, is due to the blockade of central adrenergic receptors.

Pharmacokinetics

After oral administration, chlorpromazine is rapidly absorbed from the gastrointestinal tract. Bioavailability is about 50%. The half-life is several hours. It is metabolized in the liver, forming both active and inactive metabolites. The half-life is quite long (4 weeks or more). It is excreted in urine and feces. Penetrates the blood-brain barrier, while the concentration of chlorpromazine in the brain exceeds its concentration in plasma.

Indications for use

• chronic paranoid and hallucinatory-paranoid states;
• states of psychomotor agitation in patients with schizophrenia (hallucinatory-delusional, hebephrenic, catatonic syndromes);
• alcoholic psychosis, manic agitation in patients with manic-depressive psychosis;
• mental disorders in patients with epilepsy;
• agitated depression in patients with presenile, manic-depressive psychosis;
• neurotic diseases, accompanied by increased muscle tone;
• pain, incl. causalgia (in combination with analgesics);
• persistent sleep disorders (in combination with sleeping pills and tranquilizers);
• Meniere's disease;
• vomiting of pregnant women;
• treatment and prevention of vomiting during treatment with antineoplastic agents and during radiation therapy;
• itchy dermatoses;
• as part of "lytic mixtures" in anesthesiology

Method of administration and dosage

The dosage regimen is set individually. For adults, the daily dose is 25-600 mg; the maximum single dose is 300 mg; the maximum daily dose is 1.5 g.

Children are prescribed in a daily dose at the rate of 1 mg / kg of body weight.

Side effect

Possibly: hypotension, tachycardia, dyspeptic symptoms, dry skin, decreased salivation.

Rarely (with prolonged use in high doses): neuroleptic syndrome, prolonged depression, extrapyramidal disorders; pigmentation of the skin, clouding of the lens; allergic reactions.

In isolated cases: toxic hepatitis, agranulocytosis, thrombophlebitis.

Contraindications

• impaired liver and / or kidney function;
• dysfunction of the hematopoietic organs;
• progressive systemic diseases of the brain and spinal cord;
• myxedema;
• decompensated heart defects;
• thromboembolic disease;
• late stage of bronchiectasis;
• coma;
• brain injury

special instructions

With caution, under close supervision, the drug should be prescribed for cholelithiasis and urolithiasis, acute pyelitis, rheumatism, rheumatic heart disease.

It is not recommended to use Aminazin for gastric ulcer and duodenal ulcer. With prolonged use of the drug, it is necessary to control the picture of peripheral blood, prothrombin index, liver and kidney function, neurological examinations and consultations of an ophthalmologist. In experimental studies, the embryotoxic effect of the drug was established.

Drug interactions

Aminazine enhances the effect of hypnotics, opioid analgesics, agents for general and local anesthesia. The effect of anticonvulsants under the influence of Aminazine is enhanced, but in some cases, Aminazine can cause convulsive phenomena. Incompatible with MAO inhibitors. Long-term combination with analgesics-antipyretics is undesirable.

Release form

10 pills, 50 mg each
500 pills, 50 mg each
10 pills 100 mg each
400 pills 100 mg each

A drug Aminazin- antipsychotic agent, has a calming effect on the nervous system.
Chlorpromazine is a neuroleptic of the group of aliphatic phenothiazine derivatives. Shows a pronounced antipsychotic effect, eliminates psychomotor agitation. reduces the feeling of fear, aggressiveness, psychomotor retardation. In addition to neuroleptic and sedative, it has antiemetic, hypothermic, hypotensive and antiserotonin effects. Blocks central and dopaminergic interneuronal contacts. It potentiates the action of analgesics, local anesthetics, hypnotics and anticonvulsants.

Pharmacokinetics

... Chlorpromazine is metabolized in the liver, forming both active and inactive metabolites. It is excreted in urine and feces, passes through the blood-brain barrier, while its concentration in the brain exceeds the concentration in blood plasma. The half-life is quite long (4 weeks or more).

Indications for use

Indications for the use of the drug Aminazin are: chronic paranoid and hallucinatory-paranoid states, states of psychomotor agitation in patients with schizophrenia (hallucinatory-delusional, hebephrenic, catatonic syndromes), alcoholic psychosis, manic agitation in patients with manic-depressive psychosis, mental disorders in patients with epilepsy , manic-depressive psychosis, as well as in other diseases, accompanied by excitement, stress. Neurotic diseases accompanied by increased muscle tone. Persistent pain, including causalgia (in combination with analgesics), persistent sleep disturbance (in combination with hypnotics and tranquilizers). Meniere's disease, vomiting in pregnant women, treatment and prevention of vomiting in the treatment of anticancer drugs and radiation therapy. Dermatous itching. As part of "lytic mixtures" in anesthesiology.

Mode of application

A drug Aminazin are prescribed intramuscularly and intravenously. The doctor sets the doses and treatment regimens individually, depending on the indications and the patient's condition. When administered intramuscularly, the highest single dose is 150 mg, the daily dose is 600 mg. Usually 1-5 ml of a 2.5% solution is injected intramuscularly no more than 3 times a day. The course of treatment is several months, in high doses - up to 1.5 months, then they switch to treatment with maintenance doses, gradually reducing the dose by 25-75 mg per day. With acute mental agitation, 100-150 mg (4-6 ml of a 2.5% solution) is injected intramuscularly or 25-50 mg intravenously (1-2 ml of a 2.5% chlorpromazine solution is diluted in 20 ml of a 5% or 40% glucose solution) , if necessary, 100 mg (4 ml of a 2.5% solution - in 40 ml of glucose solution). Enter slowly. When administered intravenously, the highest single dose is 100 mg, the daily dose is 250 mg.
With intramuscular or intravenous administration to children over the age of 1 year, a single dose is 250-500 kmg / kg of body weight; children over the age of 5 years (body weight up to 23 kg) - 40 mg per day, 5-12 years (body weight - 23-46 kg) - 75 mg per day.
Weakened patients and elderly patients are prescribed up to 300 mg per day intramuscularly or up to 150 mg per day - intravenously.

Side effects

From the side of the central nervous system: with prolonged use, the development of neuroleptic syndrome is possible: parkinsonism, akathisia, mental indifference and other changes in the psyche, a delayed reaction to external stimuli, blurred vision; rarely - dystonic extrapyramidal reactions, tardive dyskinesia, neuroleptic depression, impaired thermoregulation, neuroleptic malignant syndrome; in isolated cases - convulsions, insomnia, agitation.
From the side of the cardiovascular system: possible arterial hypotension (especially with intravenous administration), tachycardia; very rarely - changes in the ECG (lengthening of the QT interval, depression of the ST segment, changes in the T and U waves, arrhythmia).
From the digestive tract: rarely - cholestatic jaundice, nausea, vomiting; very rarely - dry mouth.
On the part of the hematopoietic system: rarely - leukopenia, agranulocytosis.
From the urinary system: rarely - difficulty urinating; very rarely - priapism.
From the endocrine system: menstrual irregularities, impotence, gynecomastia, weight gain; very rarely - galactorrhea.
Allergic reactions: possible skin rashes, itching; rarely - exfoliative dermatitis, erythema multiforme; very rarely - angioedema, bronchospasm, urticaria, systemic lupus erythematosus.
Dermatological reactions: rarely - skin pigmentation, photosensitivity. If solutions get on mucous membranes, on the skin and under the skin - tissue irritation; after intramuscular injection - often the appearance of painful infiltrates at the injection site; with intravenous administration, damage to the vascular endothelium is possible. To prevent these phenomena, chlorpromazine solutions are diluted with solutions of novocaine, glucose, 0.9% sodium chloride solution.
From the side of the organs of vision: with prolonged use in high doses, chlorpromazine may be deposited in the anterior structures of the eye (cornea and lens), which can accelerate the processes of natural aging of the lens.

Contraindications

:
Contraindications to the use of the drug Aminazin are: increased individual sensitivity to chlorpromazine or to other components of the drug. Damage to the liver (cirrhosis, hepatitis, hemolytic jaundice, cholelithiasis), kidney (nephritis, acute pyelitis, kidney amyloidosis, urolithiasis), diseases of the hematopoietic organs, progressive systemic diseases of the brain and spinal cord (slow neuroinfections, multiple sclerosis), decompensated heart failure , severe cardiovascular diseases, gastric and duodenal ulcers during an exacerbation, decompensated heart defects, severe arterial hypotension, thromboembolic disease, severe myocardial dystrophy, rheumatic heart disease in the later stages, myxedema, late stage bronchiectatic glaucoma, obstructed glaucoma, occluded prostate gland, severe depression of the central nervous system, coma, brain injury. Do not administer concurrently with barbiturates. alcohol, drugs.

Pregnancy

:
If necessary, use Aminazina during pregnancy, the duration of treatment should be limited, and in the third trimester of pregnancy, the dose should be reduced if possible. It must be borne in mind that chlorpromazine prolongs labor.
When using chlorpromazine in high doses, pregnant women in newborns sometimes noted indigestion associated with atropine-like action, extrapyramidal syndrome. If it is necessary to use the drug, you must stop breastfeeding. Aminazine and its metabolites cross the placental barrier and into breast milk.

Interaction with other medicinal products

The sedative effect of chlorpromazine is enhanced by simultaneous use with zolpidem mlm zopiclone; neuroleptic - with estrogen.

The concentration of chlorpromazine in the blood plasma is reduced by antacids containing aluminum and magnesium hydroxide (they increase the absorption of chlorpromazine from the digestive tract), barbiturates (they increase the metabolism of chlorpromazine in the liver). The concentration of chlorpromazine in the blood plasma is increased by chloroquine, sulfadoxine / pyrimethamine. Cimetidine may decrease or increase the concentration of chlorpromazine in the blood.
Chlorpromazine can reduce or further completely inhibit the antihypertensive effect of guanethidine, increase the concentration of imipramine in the blood, inhibit the effect of levodopa; increase or decrease the concentration of phenytoin in the blood, reduce the action of cardiac glycosides.
With simultaneous use with other drugs, it is possible: with anticholinergics - increased anticholinergic action; with anticholinesterase agents - muscle weakness, aggravation of the course of myasthenia gravis; with epinephrine - distortion of the effects of the latter, as a result of which there is a further decrease in blood pressure and the development of severe arterial hypotension and tachycardia; with amitriptyline - an increase in the risk of developing tardive dyskinesia, the development of paralytic ileus is possible; with diazoxide - severe hyperglycemia; with doxepin - potentiation of hyperpyrexia; with lithium carbonate - pronounced extrapyramidal symptoms, neurotoxic effect; with morphine - the development of myoclonus; with cisapride - additive lengthening of the QT interval on the ECG; with nortriptyline in patients with schizophrenia - a worsening of the clinical condition is possible, despite the increased level of chlorpromazine in the blood; with tricyclic antidepressants, mono-monoxidase inhibitors - an increased risk of developing neurolytic malignant syndrome; with drugs for the treatment of hyperthyroidism - the risk of developing agranulocytosis increases; with other drugs that cause extrapyramidal reactions - an increase in the frequency and severity of extrapyramidal disorders is possible; with drugs that cause arterial hypotension - severe orthostatic hypotension is possible; with ephedrine - it is possible to weaken the vasoconstrictor effect of ephedrine.
With neurotic diseases, which are accompanied by an increase in muscle tone, persistent pain, including causalgia, chlorpromazine can be combined with analgesics, with persistent insomnia - with hypnotics and tranquilizers. With the simultaneous use of chlorpromazine with anticonvulsants, the effect of the latter is enhanced; with other drugs that inhibit the effect on the central nervous system, as well as with ethanol and drugs containing ethanol, it is possible to increase the depression of the central nervous system, as well as respiratory depression.
Barbiturates increase the metabolism of chlorpromazine, stimulating microsomal liver enzymes and thereby reducing its concentration in blood plasma, as a result, a therapeutic effect. The drug can inhibit the action of amphitamines, levodopa, clonidine, guanedine, adrenaline.

Overdose

:
Cases of drug overdose Aminazin not described. To prevent overdose, it is necessary to strictly adhere to the recommended doses of the drug.
In case of collaptoid conditions, the introduction of cordiamine, caffeine, mezaton is recommended. With the development of dermatitis, treatment with chlorpromazine is stopped and antihistamines are prescribed. Neurological complications usually decrease with decreasing chlorpromazine dose, and they can also be reduced by a single administration of cyclodol or tropacin.
After prolonged use of large doses of the drug (0.5-1.5 g per day), in isolated cases, jaundice, accelerated blood coagulation, lymph and leukopenia, anemia, agranulocytosis, skin pigmentation, lens and corneal opacities may be observed.

Storage conditions

Store in a dark place at a temperature not exceeding 25 ° C.
Keep out of the reach of children.

Release form

Aminazine - injection. 2 ml in an ampoule, 10 ampoules in a blister, 1 blister in a pack; 2 ml in an ampoule, 10 ampoules in a box.

Compound

:
1 ml solution Aminazin contains chlorpromazine hydrochloride 25 mg; excipients: anhydrous sodium sulfite (E 221), sodium metabisulfite (E 223), ascorbic acid, sodium chloride, water for injection.

Additionally

:
It is not recommended to use the drug Aminazin patients with hypothyroidism, pheochromocytoma, myasthenia gravis.
With extreme caution, under close supervision, the drug is used to treat patients with pathological changes in the blood picture, rheumatism, rheumatic heart disease, alcohol intoxication, Reye's syndrome, as well as breast cancer, severe arterial hypertension, a tendency to develop glaucoma, Parkinson's disease, chronic organ diseases breathing (especially in children), epileptic seizures.
It is necessary to prescribe with caution to elderly patients (increased risk of excessive sedative and hypotensive effects), emaciated and debilitated patients.
If hyperthermia develops, which is one of the symptoms of neuroleptic malignant syndrome, the drug should be discontinued immediately.
In children, especially with acute illnesses, when using the drug, there is a greater risk of developing extrapyramidal symptoms.
With long-term treatment with the drug, it is necessary to control the blood composition, prothrombin index, liver and kidney function. After injection of the drug, patients need to lie down for 1-1.5 hours; an abrupt transition to an upright position can cause orthostatic collapse.
Antidepressants and central nervous system stimulants are used to reduce neurolytic depression. During the period of therapy, due to the possibility of photosensitization of the skin, prolonged exposure to the sun should be avoided. The drug does not exhibit antiemetic action when nausea is a consequence of vestibular stimulation or local irritation of the digestive tract. When using the drug, patients with atony of the digestive tract and achilia are recommended to simultaneously prescribe gastric juice or hydrochloric acid (due to the inhibitory effect of chlorpromazine on motility and secretion of gastric juice), monitor diet and intestinal function. In patients who are using the drug, the need for riboflavin may be increased.
Antipsychotic phenothiazines can increase the prolongation of the QT interval, which increases the risk of ventricular arrhythmias, including those of the "pirouette" type, which can potentially lead to sudden death. Before prescribing the drug, the patient should be examined (biochemical status, ECG) in order to exclude possible risk factors (for example, heart disease, a history of QT interval prolongation, metabolic disorders such as hypokalemia, hypocalcemia, hypomagnesemia; fasting, alcohol abuse, concomitant therapy with others drugs that cause lengthening of the QT interval). It is necessary to monitor the ECG at the beginning of drug treatment and, if necessary, during treatment.
The ability to influence the reaction rate when driving or operating other mechanisms. During treatment with chlorpromazine, it is necessary to refrain from driving or working with other mechanisms.

Main settings

Name:	AMINAZINE
ATX code:	N05AA01 -